Kymera Therapeutics Reports Tomorrow After Telling Everyone Exactly When for a Week Straight

Kymera Therapeutics (KYMR) reports first-quarter 2026 results on April 30, 2026, before market open, with analysts expecting a loss of $0.89 per share. The clinical-stage biotech has missed estimates in three of its last four quarters, and investors will be watching closely for signs the company can reverse this trend while advancing its pipeline of targeted protein degradation therapies. With the stock trading below most short-term moving averages but holding above longer-term support, the technical setup heading into the print reflects cautious optimism tempered by recent execution concerns.

Part 1: Earnings Preview

Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) to develop oral small molecule degrader medicines for immunological diseases. The company is focused on building a pipeline of therapies that address disease targets inaccessible with conventional treatments, having advanced the first degrader into the clinic for immunological conditions.

Kymera will report Q1 2026 earnings on April 30, 2026, before market open, with the consensus estimate calling for a loss of $0.89 per share from 10 analysts. The company most recently reported Q4 2025 results with an actual loss of $0.97 per share. Compared to the same quarter last year (Q1 2025), when Kymera posted a loss of $0.82 per share, the current estimate of -$0.89 represents an 8.54% deterioration year-over-year, signaling continued investment in clinical development.

Three key themes define this earnings story:

Pipeline Advancement and Clinical Milestones: Investors will focus on updates from Kymera's clinical programs, particularly progress in its lead degrader candidates for immunological diseases. Any data readouts, enrollment updates, or regulatory interactions could significantly impact sentiment, as the company's valuation hinges on successful clinical execution and the validation of its TPD platform.

Cash Runway and Operational Efficiency: With the company posting consistent losses as it invests in R&D, the quarterly burn rate and cash position will be scrutinized. Analysts will want clarity on how long the current cash balance can fund operations and whether any partnership deals or financing activities are on the horizon to extend the runway.

Estimate Reliability and Execution: After missing estimates in three consecutive quarters—including significant misses of 26.76% and 25.97% in Q3 and Q4 2025—investors need to see whether management can deliver results closer to guidance. The widening gap between expectations and reality has eroded confidence, making this quarter critical for rebuilding credibility.

Analyst commentary ahead of the release reflects cautious optimism. The strong buy-heavy consensus (21 strong buys out of 24 total ratings) suggests confidence in the long-term platform, but the recent string of misses has tempered near-term expectations. The average price target of $119.14 implies substantial upside from current levels, indicating analysts believe the market is undervaluing Kymera's pipeline potential despite execution challenges.

Part 2: Historical Earnings Performance

Kymera Therapeutics has demonstrated inconsistent earnings performance over the past four quarters, with a troubling pattern emerging in recent reports. The company beat estimates by 10.87% in Q1 2025, posting a loss of $0.82 versus the expected $0.92. However, the subsequent three quarters tell a different story: Q2 2025 saw a miss of 14.46% (-$0.95 actual vs. -$0.83 estimate), followed by more significant misses of 26.76% in Q3 2025 (-$0.90 vs. -$0.71) and 25.97% in Q4 2025 (-$0.97 vs. -$0.77).

The deteriorating trend is clear—losses have been consistently worse than analysts anticipated, with the magnitude of misses accelerating in the second half of 2025. The Q3 and Q4 misses were particularly pronounced, suggesting either overly optimistic analyst models or unexpected cost pressures and development setbacks that management failed to telegraph effectively. This pattern raises concerns about visibility and guidance quality heading into the Q1 2026 report.

For the upcoming quarter, the consensus estimate of -$0.89 represents a 8.54% increase in losses compared to the -$0.82 reported in the same quarter last year. Given the recent track record, investors should approach this estimate with caution—the company has missed by an average of over 20% in the past two quarters, and any similar shortfall could trigger a negative market reaction.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Kymera Therapeutics typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around Kymera's earnings releases shows significant volatility, with an average absolute Day 0 move of 4.38% and Day 0 trading ranges averaging 11.09%. The most recent report on February 26, 2026, produced the largest reaction in the dataset—a 4.80% gain on Day 0 with an intraday range of 13.42%, followed by a 3.87% decline on Day +1. This whipsaw pattern suggests initial optimism gave way to profit-taking or deeper analysis of the results.

Looking across the eight-quarter history, Day 0 moves have been mixed in direction but consistently substantial in magnitude, ranging from a 14.45% decline (February 2025) to a 4.80% gain (most recent). Day +1 follow-through has averaged 3.53% in absolute terms, indicating that earnings reactions often extend into the second session. The February 2025 report stands out as particularly volatile, with a 17.32% intraday range on Day 0, likely reflecting a significant miss or unexpected guidance.

Investors should prepare for meaningful price movement—the historical pattern suggests a Day 0 swing of 4-5% is typical, with potential for much larger moves if results or commentary deviate significantly from expectations. The recent trend of larger Day 0 ranges (above 10% in four of the last five reports) indicates heightened uncertainty and active positioning around the print.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 15.23% for the May 15 expiration, significantly higher than the historical average Day 0 move of 4.38% and even exceeding the average Day 0 intraday range of 11.09%. This elevated implied volatility suggests options traders are anticipating a more dramatic reaction than historical patterns would indicate, possibly reflecting heightened uncertainty around pipeline updates or the potential for a larger-than-usual guidance revision given the recent string of misses.

Part 3: What Analysts Are Saying

Analyst sentiment on Kymera Therapeutics remains overwhelmingly bullish despite recent execution challenges. The current consensus rating stands at 4.79 out of 5.0, with 21 strong buy ratings, 1 moderate buy, and 2 holds among the 24 analysts covering the stock. Notably, there are zero sell or strong sell ratings, indicating broad confidence in the company's long-term prospects even as near-term results have disappointed.

The average price target of $119.14 represents substantial upside of approximately 46% from the current price of $81.51, with estimates ranging from a low of $91.00 to a high of $140.00. This wide range—spanning nearly $50—reflects differing views on the timeline and probability of clinical success, but even the most conservative target implies double-digit upside.

Analyst sentiment has remained unchanged over the past month, with the rating distribution holding steady at the same levels seen a month ago. This stability suggests analysts are maintaining their conviction in the TPD platform and pipeline potential despite the recent string of earnings misses. The lack of downgrades following the Q3 and Q4 disappointments indicates the Street views these shortfalls as timing issues or investment-phase dynamics rather than fundamental concerns about the science or market opportunity.

The consensus implies analysts believe the market is significantly undervaluing Kymera's pipeline, with the 46% upside to target suggesting current levels present an attractive entry point for investors willing to look past near-term volatility and losses. However, the recent execution issues mean the company will need to deliver on clinical milestones and demonstrate improved cost discipline to justify these bullish projections.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 64% Buy signal, down from 100% Buy last week but improved from 56% Buy a month ago. This recent weakening from last week's perfect score suggests some near-term momentum has faded as the stock has pulled back heading into earnings.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming, reflecting recent consolidation
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive despite some choppiness
• Long-term (100% Buy): Strong buy signal reflects solid strength in the longer-term trend, with the stock well above its 200-day moving average

Trend Characteristics: The technical environment shows Average strength with the Weakest direction, suggesting the uptrend remains intact but is losing momentum heading into the earnings event.

Kymera is currently trading at $81.51, positioned below the 5-day ($84.82), 10-day ($86.17), 20-day ($86.47), and 50-day ($84.62) moving averages, indicating recent weakness in the short-term trend.

However, the stock remains above both the 100-day ($81.25) and 200-day ($66.84) moving averages, confirming the longer-term uptrend is still intact. The current price sits just above the 100-day average, making this a critical support level—a break below could signal further technical deterioration, while a strong earnings reaction could quickly reclaim the shorter-term averages. The setup is cautiously neutral: long-term support is holding, but the recent pullback and positioning below all short-term averages suggests the stock needs a positive catalyst from earnings to reignite momentum. The weakening directional signal and compression near the 100-day average indicate traders are waiting for the results before committing to either side.